

February 05, 2023

DCS-CRD BSE Limited First Floor, New Trade Wing Rotunda Building, Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400 023 Fax No.2272 3121/2037/2039 Stock Code: 543213	Listing Compliance National Stock Exchange of India Ltd. Exchange Plaza, 5 th Floor Plot No.C/1, 'G'Block, Bandra- Kurla Complex Bandra East Mumbai 400 051 Fax No.2659 8237/8238 Stock Code: ROSSARI
---	--

Dear Sir/Madam,

Subject.: Q3 & FY23 Press Release

Please find enclosed a copy of the Press Release for the quarter and nine months ended December 31, 2022.

The same may please be taken on record and suitably disseminated to all concerned.

Thanking you,

Yours Sincerely,
For Rossari Biotech Limited

**PARUL
GUPTA**

Digitally signed by
PARUL GUPTA
Date: 2023.02.05
10:04:02 +05'30'



Parul Gupta
Company Secretary & Compliance Officer
Membership No.: A38895

Encl.: as above

ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company), CIN: L24100MH2009PLC194818

Regd. Office : 201 A - B, 2nd Floor, Akruiti Corporate Park, L.B.S Marg, Next to GE Gardens, Kanjurmarg (W), Mumbai - 400078, India. T : +91-22-6123 3800 F : +91-22-2579 6982

Factory : Plot No. 10 & 11, Survey No. 90/1/10/ & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. T : 0260-669 3000

: Plot No. D3/24/3, Opposite Yokohama Tyre, Phase III, G.I.D.C Dahej, Village Galenda, Taluka Vagra, Bharuch-Gujarat - 392130, India. T : +91 2641-661621

Info@rossari.com

www.rossari.com



Rossari Biotech Limited

Corporate Office: 201 A & B Ackruti Corporate Park, L.B.S Marg, Next to GE Gardens, Kanjurmarg West,
Mumbai, Maharashtra 400078

Rossari Biotech announces Q3 & 9M FY23 results.

<u>Q3 FY23</u>	<u>9M FY23</u>
Revenue stood at Rs. 389.3 Cr EBITDA at Rs. 54.2 Cr PAT at Rs. 25.7 Cr	Revenue at Rs. 1,249.4 Cr EBITDA stood at Rs. 168.4 Cr PAT at Rs. 78.3 Cr

Mumbai, February 4, 2022: Rossari Biotech Limited (Rossari), a Specialty-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries, has announced its financial results for the quarter ended December 31, 2022.

Consolidated: Q3 FY23 performance overview compared with Q2 FY23

- Revenue from operations stood at Rs. 389.3 crore as against Rs. 425.4 crore
- EBITDA at Rs. 54.2 crore as against Rs. 56.5 crore
 - EBITDA margin at 13.9% as against 13.3%
- PAT stood at Rs. 25.7 crore as against Rs. 23.9 crore
- EPS (Diluted) stood at Rs. 4.6 as against Rs. 4.3

Consolidated: 9M FY23 performance overview compared with 9M FY23

- Revenue from operations stood at Rs. 1,249.4 crore as against Rs. 1,044.0 crore
- EBITDA at Rs. 168.4 crore as against Rs. 131.1 crore
 - EBITDA margin at 13.5% as against 12.6%
- PAT stood at Rs. 78.3 crore as against Rs. 73.3 crore
- EPS (Diluted) stood at Rs. 14.1 as against Rs. 13.3

Standalone: Q3 FY23 performance overview compared with Q2 FY23

- Revenue from operations stood at Rs. 236.9 crore as against Rs. 240.9 crore
- EBITDA at Rs. 31.9 crore as against Rs. 27.9 crore
 - EBITDA margin at 13.5% as against 11.6%
- PAT stood at Rs. 17.5 crore as against Rs. 15.4 crore
- EPS (Diluted) stood at Rs. 3.2 as against Rs. 2.8

Commenting on the performance, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said

“We have reported a stable performance during the quarter despite the ongoing challenging operating environment. All our standalone segments, including HPPC, Textile, and AHN, have reported stable performance. However, our subsidiaries witnessed a slowdown due to subdued demand, leading to lower consolidated HPPC sales during the quarter.

We achieved an improvement in margins on a quarter-over-quarter basis in Q3 FY23, supported by moderating raw material costs. Our gross margins increased by 95 bps and EBITDA margins improved by 62 bps, reaching 30.0% and 13.9% respectively. We have been prudently expanding our business with a focus on products with better margins. We are now seeing some stabilization in the market and we look to continue with our growth plans in the coming quarters.

Over the years, our commitment to R&D has been instrumental in establishing Rossari as a leader in the industry. We have a proven track record of developing innovative and customized chemical solutions for customers across various industries. Additionally, the integration of the acquired companies into our R&D efforts has further augmented our technical capabilities.

With a strong focus on R&D, a solid balance sheet, ample capacity, and a comprehensive product portfolio, Rossari is well-positioned to pursue opportunities in the industry. We remain optimistic that a stabilized macroeconomic environment will drive long-term sustainable growth and enable us to deliver a stronger performance in the future”

Note:

- 1) All figures, unless mentioned otherwise, are on a consolidated basis
- 2) EPS not annualized
- 3) Rossari completed the acquisition of Unitop Chemicals Private Limited (UCPL) and Tristar Intermediates Private Limited (TIPL) on 26th August, 2021 and 30th August, 2021 respectively. Accordingly, the results for current nine months and nine months ended 31st December, 2021 (corresponding nine months) are not comparable.

About Rossari Biotech Limited:

Rossari Biotech Limited (Rossari) (BSE: 543213, NSE: ROSSARI), is a Speciality-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. Headquartered at Mumbai, India, the Company operates strategically located manufacturing facilities at Silvassa and Dahej. The Company offers tailor-made solutions for Home, Personal Care and Performance chemicals (HPPC), Textile speciality chemicals and Animal Health and Nutrition (AHN). With differentiated product offerings, Rossari caters to an array of applications across FMCG, Home care, Industrial Cleaning, Personal Care, Textile Speciality Chemicals, Performance Chemicals, the Animal Health and Nutrition and Pet Care businesses. The Company has an extensive and a dedicated network of distributors spread all over India.

For more information, please visit www.rossari.com OR contact:

Manasi Nisal

Rossari Biotech Limited

Tel: +91 22 6123 3800

Email: manasi.nisal@rossari.com

Anoop Poojari / Aesha Shah

CDR India

Tel: +91 98330 90434 / 9867250569

Email: anoop@cdr-india.com /
aesha@cdr-india.com

DISCLAIMER:

Certain statements and opinions with respect to the anticipated future performance of Rossari Biotech Limited in the press release ("forward-looking statements"), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to be correct. Such forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changes in economic, political, regulatory, business or other market conditions. Such forward-looking statements only speak as at the date the press release is provided to the recipient and Rossari Biotech Limited is not under any obligation to update or revise such forward-looking statements to reflect new events or circumstances. No representation or warranty (whether express or implied) is given in respect of any information in this press release or that this press release is suitable for the recipient's purposes. The delivery of this press release does not imply that the information herein is correct as at any time subsequent to the date hereof and Rossari Biotech Limited has no obligation whatsoever to update any of the information or the conclusions contained herein or to correct any inaccuracies which may become apparent subsequent to the date hereof.